BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) are significant problems in cancer patients, but a correlation between plasma aprepitant concentration and antiemetic effect has not been reported. This study aimed to characterize the correlation between plasma aprepitant concentration and clinical antiemetic effect in a limited group of Japanese gastric or esophageal cancer patients. METHODS: Thirty-three Japanese cancer patients receiving cisplatin-based chemotherapy for the first time following oral aprepitant (125 mg on day 1 and 80 mg on days 2 and 3) were enrolled. The plasma aprepitant concentrations 48 h after the first administration were determined using liquid chromatography-mass spectrometry. Patients were allocated to the high-concentration group (plasma aprepitant concentration was >331.1 ng/ml) or the low-concentration group (plasma aprepitant concentration was ≤ 331.1 ng/ml) to investigate the relationship between plasma aprepitant concentration and antiemetic effects. RESULTS: No significant differences were found between the two groups in terms of percentage of CINV prevention. Of 13 patients who experienced CINV [MASCC Antiemesis Tool (MAT) score >3], those in the high-concentration group showed a significant improvement in CINV following aprepitant administration (days 1-3). CONCLUSION: The present study suggests that the antiemetic effect of aprepitant is associated with plasma aprepitant concentration. A plasma aprepitant concentration of 331.1 ng/ml may be a valid threshold for identifying its optimal antiemetic effects in Japanese gastric or esophageal cancer patients.
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) are significant problems in cancerpatients, but a correlation between plasma aprepitant concentration and antiemetic effect has not been reported. This study aimed to characterize the correlation between plasma aprepitant concentration and clinical antiemetic effect in a limited group of Japanese gastric or esophageal cancerpatients. METHODS: Thirty-three Japanese cancerpatients receiving cisplatin-based chemotherapy for the first time following oral aprepitant (125 mg on day 1 and 80 mg on days 2 and 3) were enrolled. The plasma aprepitant concentrations 48 h after the first administration were determined using liquid chromatography-mass spectrometry. Patients were allocated to the high-concentration group (plasma aprepitant concentration was >331.1 ng/ml) or the low-concentration group (plasma aprepitant concentration was ≤ 331.1 ng/ml) to investigate the relationship between plasma aprepitant concentration and antiemetic effects. RESULTS: No significant differences were found between the two groups in terms of percentage of CINV prevention. Of 13 patients who experienced CINV [MASCC Antiemesis Tool (MAT) score >3], those in the high-concentration group showed a significant improvement in CINV following aprepitant administration (days 1-3). CONCLUSION: The present study suggests that the antiemetic effect of aprepitant is associated with plasma aprepitant concentration. A plasma aprepitant concentration of 331.1 ng/ml may be a valid threshold for identifying its optimal antiemetic effects in Japanese gastric or esophageal cancerpatients.
Authors: Anup K Majumdar; Laura Howard; Michael R Goldberg; Lisa Hickey; Marvin Constanzer; Paul L Rothenberg; Tami M Crumley; Deborah Panebianco; Thomas E Bradstreet; Arthur J Bergman; Scott A Waldman; Howard E Greenberg; Kathleen Butler; A Knops; Inge De Lepeleire; Nicole Michiels; Kevin J Petty Journal: J Clin Pharmacol Date: 2006-03 Impact factor: 3.126
Authors: Mats Bergström; Richard J Hargreaves; H Donald Burns; Michael R Goldberg; David Sciberras; Scott A Reines; Kevin J Petty; Mattias Ogren; Gunnar Antoni; Bengt Långström; Olli Eskola; Mika Scheinin; Olof Solin; Anup K Majumdar; Marvin L Constanzer; Wendy P Battisti; Thomas E Bradstreet; Cynthia Gargano; Jarmo Hietala Journal: Biol Psychiatry Date: 2004-05-15 Impact factor: 13.382
Authors: Rosa I Sanchez; Regina W Wang; Deborah J Newton; Ray Bakhtiar; Ping Lu; Shuet-Hing Lee Chiu; David C Evans; Su-Er W Huskey Journal: Drug Metab Dispos Date: 2004-08-10 Impact factor: 3.922
Authors: F Roila; M Tonato; C Basurto; M Picciafuoco; S Bracarda; D Donati; P Malacarne; L Monici; F Di Costanzo; L Patoia Journal: J Clin Oncol Date: 1989-11 Impact factor: 44.544
Authors: Alexander Molassiotis; Peter A Coventry; Carrie T Stricker; Caroline Clements; Beth Eaby; Luke Velders; Cynthia Rittenberg; Richard J Gralla Journal: J Pain Symptom Manage Date: 2007-05-23 Impact factor: 3.612